NCT00467519View on ClinicalTrials.gov

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

1,045

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
TetanusDiphtheriaPertussis
Interventions
BIOLOGICAL

Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)

0.5 mL, IM

BIOLOGICAL

DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)

0.5 mL, IM

Trial Locations (43)

14618

Rochester

15236

Pittsburgh

15241

Pittsburgh

15401

Uniontown

16505

Erie

19046

Rydal

19401

Norristown

21702

Frederick

23113

Midlothian

23321

Chesapeake

30062

Marietta

30189

Woodstock

35205

Birmingham

35244

Birmingham

37388

Tullahoma

37660

Kingsport

40004

Bardstown

40291

Louisville

41017

Crestview Hills

44121

Cleveland

54601

La Crosse

58103

Fargo

68123

Bellevue

68124

Omaha

68131

Omaha

68132

Omaha

71111

Bossier City

72205

Little Rock

72401

Jonesboro

72703

Fayetteville

78229

San Antonio

84041

Layton

84663

Springville

92647

Huntington Beach

92708

Fountain Valley

94611

Oakland

95661

Roseville

95815

Sacramento

97030

Gresham

99202

Spokane

99218

Spokane

06360

Norwich

T6G 2C8

Edmonton

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00467519 - Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age | Biotech Hunter | Biotech Hunter